Objective derivation of the morphology and staging of visual field loss associated with long-term vigabatrin therapy
Video 1: Video of the rolling median of the 78 modelled fields from the 87 individuals who had been exposed to vigabatrin and who had undertaken the Full Field 135 Point Test with the three zone age-corrected strategy.
Video 2: Video of the rolling median of the 90 modelled fields from the 99 individuals who had been exposed to vigabatrin and who had undertaken the Central 30-2 Threshold Test.
Video 3: Video of the rolling median of the 54 modelled fields from the 63 individuals who had been exposed to vigabatrin and who had undertaken the combined Full Field 135 Point Test with the three zone age-corrected strategy and the Central 30-2 Threshold Test.
Video 4: Video of the rolling median of the 29 modelled fields from the 38 individuals with no exposure to vigabatrin and who had undertaken the combined Full Field 135 Point Test with the three zone age-corrected strategy and the Central 30-2 Threshold Test.
Disclosures
Funding None
Conflicts of interest John M Wild, Phillip EM Smith and Carlo Knupp declare that they have no conflicts of interest.
Ethical approval All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Local Research and Ethics Committee ruled that approval was not required for this study. The visual field assessments were considered to be part of normal good clinical practice. The visual fields were de-identified and so written informed consent was not required.
Data availability The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.
Copyright
This video is distributed under the terms of the Creative Commons Attribution Noncommerical Licence which permits any noncommerical use, distribution, and reproduction in any medium, provided the original author(s) and the source is credited.
